Author: Schiller J.T. Lowy D.R.
Publisher: Academic Press
ISSN: 1044-579X
Source: Seminars in Cancer Biology, Vol.7, Iss.6, 1996-12, pp. : 373-382
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Human papillomavirus-like particles (VLPs), self-assembled after high level expression of the papillomavirus L1 virion capsid protein in non-mammalian cells, are attractive candidates for a subunit vaccine to prevent genital HPV infection and the subsequent development of cervical cancer. In animal studies, purified VLPs induce high titers of antibodies against conformational type specific L1 epitopes. These antibodies neutralize homologous virions in in-vitro assays and protect against experimental challenge in several animal models. The encouraging results in animals justify the initiation of human trials of HPV VLP-based vaccines. Factors to be considered when designing these trials are discussed.
Related content
Current Cancer Therapy Reviews, Vol. 6, Iss. 2, 2010-05 ,pp. :
By Hallez Sophie Simon Philippe Maudoux Frédéric Doyen Jean Noël Jean-Christophe Beliard Aude Capelle Xavier Buxant Frédéric Fayt Isabelle Lagrost Anne-Cécile Hubert Pascale Gerday Colette Burny Arsène Boniver Jacques Foidart Jean-Michel Delvenne Philippe Jacobs Nathalie
Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. :
By Du Juan Näsman Anders Carlson Joseph W. Ramqvist Torbjörn Dalianis Tina
Acta Oncologica, Vol. 50, Iss. 8, 2011-11 ,pp. :